Mark Beresford

Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial

Leisha A. Emens, Francisco J. Esteva, Mark Beresford et al. · The Lancet Oncology · 2020 · 375 citations

Medicine, Oncology, Pharmacology +17

Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2–Positive Metastatic Bladder Cancer

Thomas Powles, Robert Huddart, Tony Elliott et al. · Journal of Clinical Oncology · 2017 · 202 citations · Full text

Medicine, Oncology, Pharmacology +16

Clinical and patient‐reported outcomes of <scp>SPARE</scp> – a randomised feasibility study of selective bladder preservation versus radical cystectomy

Robert Huddart, Alison Birtle, Lauren Maynard et al. · British Journal of Urology · 2017 · 166 citations · Full text

Medicine, Oncology, Surgery +17

Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received

David E. Neal, Chris Metcalfe, Jenny Donovan et al. · European Urology · 2019 · 150 citations · Full text

Medicine, Surgery, Urology +17

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi et al. · Annals of Oncology · 2019 · 113 citations · Full text

Medicine, Oncology, Pharmacology +17